MY148457A - Combination preparations comprising slv308 and a dopamine agonist - Google Patents

Combination preparations comprising slv308 and a dopamine agonist

Info

Publication number
MY148457A
MY148457A MYPI20085078A MYPI20085078A MY148457A MY 148457 A MY148457 A MY 148457A MY PI20085078 A MYPI20085078 A MY PI20085078A MY PI20085078 A MYPI20085078 A MY PI20085078A MY 148457 A MY148457 A MY 148457A
Authority
MY
Malaysia
Prior art keywords
slv308
dopamine agonist
combination preparations
acceptable salt
pharmacologically acceptable
Prior art date
Application number
MYPI20085078A
Inventor
Andrew C Mccreary
Gustaaf J M Van Scharrenburg
Martinus Th M Tulp
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Publication of MY148457A publication Critical patent/MY148457A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A COMPOSITION CONTAINING SLV308 OR ITS N-OXIDE, OR AT LEAST ONE PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF: AND L-DOPA OR AT LEAST ONE PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF, FOR SIMULTANEOUS, SEPARATE OR SEQUENTIAL USE IN THE TREATMENT OF DISORDERS REQUIRING RECOVERY OF DOPAMINERGIC FUNCTION USING THIS COMPOSITION, INCLUDING PARKINSON'S DISEASE AND RESTLESS LEG SYNDROME.
MYPI20085078A 2006-06-16 2007-06-15 Combination preparations comprising slv308 and a dopamine agonist MY148457A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81405106P 2006-06-16 2006-06-16
EP06115583 2006-06-16

Publications (1)

Publication Number Publication Date
MY148457A true MY148457A (en) 2013-04-30

Family

ID=38434785

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20085078A MY148457A (en) 2006-06-16 2007-06-15 Combination preparations comprising slv308 and a dopamine agonist

Country Status (10)

Country Link
EP (1) EP2035002A1 (en)
JP (1) JP2009539941A (en)
KR (1) KR20090031908A (en)
AU (1) AU2007259255A1 (en)
CA (1) CA2654719A1 (en)
EA (1) EA015073B1 (en)
IL (1) IL195532A0 (en)
MY (1) MY148457A (en)
NO (1) NO20090164L (en)
WO (1) WO2007144421A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0027020D0 (en) 2000-11-03 2000-12-20 Univ Manchester Treatment of movement disorders
US20090247537A1 (en) * 2008-03-25 2009-10-01 William Dale Overfield Methods for preventing or treating bruxism using dopaminergic agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7596407B2 (en) * 2004-03-26 2009-09-29 Solvay Pharmaceuticals, B.V. Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds
US8691277B2 (en) * 2004-09-21 2014-04-08 Shandong Luye Pharmaceutical Co., Ltd. Long acting sustained-release formulation containing dopamine receptor agonist and the preparation method thereof
ATE417834T1 (en) * 2005-08-22 2009-01-15 Solvay Pharm Bv N-OXIDES AS PRODRUGS OF PIPERAZINE AND PIPERIDINE DERIVATIVES

Also Published As

Publication number Publication date
EP2035002A1 (en) 2009-03-18
KR20090031908A (en) 2009-03-30
AU2007259255A1 (en) 2007-12-21
NO20090164L (en) 2009-01-14
JP2009539941A (en) 2009-11-19
IL195532A0 (en) 2009-09-01
CA2654719A1 (en) 2007-12-21
EA015073B1 (en) 2011-04-29
WO2007144421A1 (en) 2007-12-21
EA200970021A1 (en) 2009-06-30

Similar Documents

Publication Publication Date Title
MX2010013020A (en) Methods and compositions for sleep disorders and other disorders.
LU93321I2 (en) IBRUTINIB, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
TWI320316B (en) Methods for inhibiting hscd activity,pyridazine derivatives and use and pharmaceutical composition thereof
IL186200A (en) Use of amylin and amylin agonists, analogs and derivatives for the preparation of medicaments for treating psychiatric diseases
MX2009011358A (en) Pyrimidinone derivatives and methods of use thereof.
MX2009011359A (en) Pyrimidinone derivatives and methods of use thereof.
CL2007000789A1 (en) Malonamide derived compounds, gamma-secretase inhibitors; Preparation process; pharmaceutical composition; and its use in the treatment of Alzheimer's disease.
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
MX2010004450A (en) Bicyclic heterocycle derivatives and methods of use thereof.
UA97795C2 (en) Deuterated catecholamine derivatives and medicaments comprising said compounds
MX2009011357A (en) Tetrahydropyrido[4,3-d]pyrimidinone derivatives and methods of use thereof.
MX2009000900A (en) Substituted imidazolone derivatives, preparation and uses.
SG150531A1 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
EP1261340A4 (en) Compositions and methods for the treatment of parkinson's disease
MY149854A (en) Novel aminoalcohol-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
LT2008075A (en) N-carbamoylmethyl-4(r)-phenyl-2-pyrrolidinone, method of its preparation and pharmaceutical use
TW200801022A (en) Novel amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments
WO2004069146A3 (en) L-dopa amide derivatives and uses thereof
MX2010006204A (en) 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressine-dependent diseases.
UA93709C2 (en) 12-imidazolyl-1-dodecanol and use thereof in the preparation of pharmaceutical compositions
WO2007144422A3 (en) Combination preparations comprising bifeprunox and l-dopa
CL2007001517A1 (en) Compounds derived from carboxamide; preparation procedure; pharmaceutical composition comprising said compound; and use of the compound for the treatment of pain, in therapy of functional gastrointestinal disorders, irritable bowel syndrome, cancer, parkinson's, Alzheimer's, cardiovascular disorders.
EA202091356A1 (en) A2a ANTAGONISTS AS AMPLIFIERS OF Cognitive and motor functions
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
HRP20100373T1 (en) Use of a combination of morphine and at least one opiate antagonist for treatment of opiate dependency and for prevention of non-oral opiate abuse in opiate addicts